Top HIV News of 2016

Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.

Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.

RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.

Twice-daily metronidazole dosing had outcomes comparable with those of thrice-daily dosing for confirmed anaerobic infections, minimizing drug exposure and cost while maintaining clinical efficacy.

Treated patients also had fewer postacute hospitalizations and deaths, but individuals without risk factors saw no benefit.

Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.

CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.

VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.